Royalty Report: Drugs, Disease, Therapeutic – Collection: 372530

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Drug Discovery
  • Medical
  • Supply
  • Stem cells
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372530

License Grant
For the License Grant;
—  Licensor grants an exclusive license under the Licensed Technology to research, Develop, use, Commercialize, market, sell and distribute the Product for the Field in the Territory, and,
—  Licensor grants a non-exclusive right and license under the Licensed Technology to Manufacture or have Manufactured the Product for the Field in the Territory.

For the Option Grant, Licensor grants an exclusive option to an exclusive license to Products in the Territory for each Additional Indication on the same terms and conditions as provided for Indications in the Field.

License Property
The Patents titles include
Methods For Treating Adhesive Capsulitis;
Amelioration Of Dupuytrens Disease;
Methods For Treating Cellulite;
Reduction of Adipose Tissue;
Amelioration of Peyronies Disease;
Method of Enhancing the Regeneration of Injured Nerves and Adhesive Pharmaceutical Formulation Therefor;
High Dosage Topical Forms of Collagenase; and,
Treatment of Duputyrens Disease With Collagenase.

Licensor controls certain Patents and Know-How related to the Enzyme and the Product.

Licensor Product shall mean any pharmaceutical product that includes Enzyme as an active ingredient and is under development for an Indication, or is indicated for use, outside the Field.

Enzyme shall mean the purified form of the enzyme currently identified as Collagenase ABC.

Additional Indication shall mean any Indication for a Product outside of the Field.

Field of Use
The Field shall mean the prevention or treatment of Dupuytrens Disease, Peyronies Disease and Adhesive Capsulitis, otherwise known as Frozen Shoulder.

Dupuytren's disease is a progressive condition that causes the fibrous tissue of the palmar fascia to shorten and thicken.
Peyronie's disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections.
Frozen shoulder, also known as adhesive capsulitis, is a condition characterized by stiffness and pain in your shoulder joint.

IPSCIO Record ID: 2998

License Grant
Licensor grants an exclusive license under the Licensed Technology to research, Develop, use, Commercialize, market, sell and distribute the Product for the Field in the Territory.

Licensor grants a non-exclusive right and license under the Licensed Technology to Manufacture or
have Manufactured the Product for the Field in the Territory.

License Property
Licensor controls certain Patents and Know-How related to the Enzyme and the Product, and has the right to grant certain rights and licenses.

The enzyme is collagenase obtained by fermentation of Clostridium histolyticum, purified by chromatography, lyophilized and substantially free from other proteinases.

The patents include
Methods For Treating Adhesive Capsulitis;
Amelioration Of Dupuytren's Disease;
Methods For Treating Cellulite;
Reduction of Adipose Tissue;
Amelioration of Pcyronie's Disease;
Method of Enhancing the Regeneration of Injured Nerves and Adhesive Pharmaceutical Formulation Therefor;
High Dosage Topical Forms of Collagenasc; and,
Treatment of Duputyren's Disease With Collagenase.

Field of Use
The Field shall mean the prevention or treatment of Dupuytren's Disease, Peyronie's Disease and Adhesive Capsulitis, otherwise known as Frozen Shoulder.

Xiaflex has a distinct mechanism of action. When injected directly into a Dupuytren’s cord, it enzymatically disrupts collagen. As a result of collagen disruption, contracture may be reduced and range of motion may be improved.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. Penises vary in shape and size, and having a curved erection isn't necessarily a cause for concern.

IPSCIO Record ID: 368520

License Grant
Licensor grants a co-exclusive license or sublicense, as applicable, including the right to sublicense, under the Licensor Technology and the Joint Collaboration Patents, to Develop the Product in the Territory for Commercialization in the Field in the Territory, and an exclusive license or sublicense, as applicable, including the right to sublicense, under the Licensor Technology and the Joint Collaboration Patents, to Commercialize the Product in the Field in the Territory.

Licensor grants an exclusive license or sublicense, as applicable, including the right to sublicense, to use the Product Trademark and Product Trade Dress solely to the extent necessary to Commercialize the Product in the Field in the Territory and Package and Label the Product for Development or Commercialization in the Field in the Territory.

Licensor grants, during the Term and from and after the expiration or termination of this Agreement, a non-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense, under any Joint Collaboration Patents for any and all uses.

License Property
The trademark is XIAFLEXâ„¢.

The patents include
Compositions and Methods for Treating Collagen-Mediated Diseases;
Amelioration of Dupuytrens Disease;
Amelioration of Peyronies Disease; and,
Method of Treating Peyronies Disease.

Licensor has developed and is currently further developing a pharmaceutical product hereinafter defined as the Product for the treatment of Dupuytren’s Contracture and Peyronie’s Disease.

Product means, in all cases excluding any dermal formulations labeled for topical administration, any dosage strength of the pharmaceutical product consisting of the lyophilized form of injectable collagenases derived from Clostridium histolyticum as the sole active pharmaceutical ingredient and a sterile diluent containing NaCl and CaCh for the reconstitution of the lyophilized collagenase.

A Competitive Product means any pharmaceutical product consisting of the colG and colH collagenase gene sequences from Clostridium histolyticum and variants thereof.

Field of Use
The Field means the treatment in humans of Dupuytrens Contracture, Peyronies Disease and such other indications as the Parties agree to include.

The strategic alliance agreement is for the development, commercialization and supply of XIAFLEXTM (clostridial collagenase for injection), a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren's contracture and Peyronie's disease.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. Penises vary in shape and size, and having a curved erection isn't necessarily a cause for concern.

IPSCIO Record ID: 44080

License Grant
The Irish Company, through an affiliate, is party to a development and license agreement, as amended, to obtain exclusive worldwide rights to develop, market and sell certain products containing Licensors enzyme, which we refer to as XIAFLEX® (Xiapex® in the European Union).
License Property
Xiaflex is a brand name for collagenase, a naturally occurring enzyme that is involved in tissue repair.
Field of Use
The licensed rights concern the development and commercialization of products for the treatment of Dupuytren’s contracture (DC), Peyronie’s Disease (PD), Adhesive Capsulitis (aka, Frozen Shoulder syndrome), cellulite, and canine lipoma, but specifically excluding, dermal formulations labeled for topical administration.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. Penises vary in shape and size, and having a curved erection isn't necessarily a cause for concern.

IPSCIO Record ID: 7323

License Grant
Under the Agreement, the Licensee has exclusive worldwide rights to develop, market and sell certain products containing the collagenase enzyme, which the Licensee refers to as Xiaflex.
License Property
The Licensed rights concern the development and commercialization of products, other than dermal formulations labeled for topical administration, and currently, our Licensed rights cover the indications of Dupuytren’s, Peyronie’s, Frozen Shoulder syndrome and, upon our optional payment of $500,000 to the Licensor, cellulite.
Field of Use
The Licensee is responsible, at our own cost and expense, for developing the formulation and finished dosage form of products and arranging for the clinical supply of products.  

Under the Agreement, the Licensee has the exclusive right to manufacture any pharmaceutical product containing the collagenase enzyme as an active ingredient
· for the indications of Dupuytren’s, Peyronie’s and Frozen Shoulder syndrome, and for any indications outside the Field which the Licensor elects not to pursue; and
. for early-stage development activities through phase II clinical trials for any indications.

The Licensee has the non-exclusive right to manufacture any pharmaceutical product containing the collagenase enzyme as an active ingredient
·  for supply to the Licensor for in vitro development; and
·  for post-phase II development (including submissions for regulatory approval) and commercialization of indications outside the Field which Licensee elects not to pursue.

The Licensee is responsible, at our cost, for performing early stage development activities for the treatment of edematous fibrosclerotic panniculopathy, more commonly known as cellulite. The Licensor has granted us an exclusive License to research, develop, manufacture and use Xiaflex in connection with this development.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. Penises vary in shape and size, and having a curved erection isn't necessarily a cause for concern.

IPSCIO Record ID: 7325

License Grant
In this collaboration agreement the Licensor granted the Licensee exclusive rights to develop and commercialize Xiaflex for the treatment of Dupuytren's contracture and Peyronie's disease in Canada, Australia, Brazil and Mexico upon receipt of the applicable regulatory approvals.

The Licensee was also granted the right of first negotiation to obtain exclusive rights to commercialize any new Xiaflex indications in the Licensee Territory during the term of the Agreement.

License Property
XIAFLEX is a collagenase clostridium histolyticum for the treatment of adult Dupuytren’s contracture (Dupuytren’s) patients with a palpable cord and Peyronie’s disease.

Dupuytren's contracture (also known as morbus Dupuytren, or Dupuytren's disease),[1] is a fixed flexion contracture of the hand due to a palmar fibromatosis,[2] where the fingers bend towards the palm and cannot be fully extended (straightened). It is an inherited proliferative connective tissue disorder which involves the palmar fascia of the hand.
Peyronie's disease or Peyronie disease (/pe?ro?'ni?/), also known as induratio penis plastica (IPP)[1] or chronic inflammation of the tunica albuginea (CITA), is a connective tissue disorder involving the growth of fibrous plaques[2] in the soft tissue of the penis affecting 5% of men.

Field of Use
Peyronie's disease is the development of fibrous scar tissue inside the penis that causes curved, painful erections. Dupuytren's contracture is a hand deformity that usually develops slowly, over years. Dupuytren's contracture affects a layer of tissue that lies under the skin of your palm. Knots of tissue form under the skin – eventually forming a thick cord that can pull one or more of your fingers into a bent position.

IPSCIO Record ID: 372532

License Grant
The University grants a worldwide exclusive license for the University Know-How in the Field and the University Patents in the Field.

The University grants a worldwide exclusive license to use the University Know-How and the University Patents to develop, manufacture, use and sell in any manner Licensed Products in the Field, except to the extent that Licensee, its Affiliates or Sublicensees enters into a material transfer agreement, clinical trial agreement or any similar agreement that allows the University to do research or clinical development.

License Property
The technology and patents are for
Methods for treating adhesive capsulitis, and,
Invention Titled Enzymatic Capsulotomy for Shoulder Adhesive Capsulitis

University has technology in regards to the use of an injectable form of collagenase for the treatment and prevention of Frozen Shoulder.

Enzyme means an enzyme constituted of collagenase obtained by fermentation of Clostridium histolyticum, purified by chromatography, lyophilized and substantially free from other proteinases, and any variants or derivatives thereof.

Indication shall mean a pharmaceutical application of injectable collagenase.

Frozen shoulder, also known as adhesive capsulitis, is a condition characterized by stiffness and pain in your shoulder joint.

Field of Use
The Field of use means the prevention or treatment of Frozen Shoulder.  Frozen Shoulder means the condition or syndrome of shoulder adhesive capsulitis or other conditions or syndromes of the shoulder.

IPSCIO Record ID: 2999

License Grant
The Licensee entered into a license agreement with a Research Foundation which granted to us and our affiliates an exclusive worldwide license, with the right to sublicense to certain third parties, to know-how owned by the Research Foundation related to the development, manufacture, use or sale of the collagenase enzyme obtained by a fermentation and purification process, and all pharmaceutical products containing the Enzyme or injectable collagenase, in each case to the extent it pertains to the treatment and prevention of Dupuytren's contracture. Our obligation to pay royalties to the Research Foundation with respect to sales by the Company, its affiliates or any sublicensee of any Dupuytren's Licensed Product in any country (including the U.S.) arises only upon the first commercial sale of such Dupuytren's Licensed Product on a country-by-country basis. Our obligation to pay royalties will continue until the later of the expiration of the last valid claim of a patent pertaining to the Dupuytren's Licensed Product; the expiration of the regulatory exclusivity period conveyed by the FDA's Orphan Product Division with respect to the Dupuytren's Licensed Product; or June 3, 2016.
Field of Use
The Licensee will pay a royalty on net sales of Xiaflex TM for the treatment and prevention of Dupuytren’s disease.  After that, all licenses granted to us under the Dupuytren's License Agreement will become fully paid, irrevocable exclusive licenses.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.